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Factors influencing the appearance and progression of renal
damage in patients with unilateral renal agenesis and remnant
kidney.
Background. Although some studies have shown that the risk
to develop proteinuria and renal insufficiency is increased in
patients with a remnant kidney (RK) or unilateral renal agen-
esis (URA), other patients maintain normal renal function and
negative proteinuria, and the reasons to explain these different
outcomes are not known.
Methods. We performed a retrospective study of 54 patients
with a severe reduction in renal mass (33 patients with URA
and 21 with RK). Follow-up was 100 ± 72 months.
Results. Twenty patients (group 1) showed normal renal func-
tion at presentation, whereas the 34 remaining (group 2) had
proteinuria, and some of them renal insufficiency. Group 2 pa-
tients were older and had a higher blood pressure and BMI
than group 1 patients. Eleven patients of group 1 remained nor-
mal throughout follow-up (group 1A), whereas the remaining
9 developed proteinuria/renal insufficiency (group 1B). BMI at
presentation was significantly higher in group 1B: 27 ± 3.6 kg/
m2 versus 21.6 ± 2.6 kg/m2, and BMI was the only factor sta-
tistically associated with the risk to develop proteinuria/renal
insufficiency in group 1. Among group 2 patients, renal function
remained stable in 20 (group 2A), and deteriorated (>50% in-
crease of baseline serum creatinine) in the remaining 14 patients
(group 2B). BMI at presentation and treatment with ACEI dur-
ing follow-up were the only factors statistically associated with
the risk for renal failure progression among group 2 patients.
Conclusion. Overweight plays a fundamental role in the ap-
pearance of proteinuria and renal damage in patients with se-
vere renal mass reduction.
Nephron loss by extensive surgical ablation in rats has
been the most commonly studied model of progressive
renal failure in the last years. The appearance of protein-
uria, glomerulosclerosis, and renal failure in this experi-
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mental model, as well as the protective influence of sev-
eral therapeutic measures [low protein diets, drugs that
block the renin-angiotensin system such as angiotensin-
converting enzyme (ACE) inhibitors, and angiotensin re-
ceptor blockers] have been extensively investigated and
have fueled many relevant discoveries in the field of re-
nal failure progression [1–5]. A great number of exper-
iments using the renal ablation model have established
that after a critical reduction in the number of function-
ing nephrons, hemodynamic changes, with an increase in
glomerular plasma flow and capillary hydraulic pressure,
and glomerular hypertrophy take place in the remain-
ing nephrons [2–5]. These maladaptive hemodynamic
and hypertrophic changes, together with an increased
production of vasoactive and profibrogenic substances
[angiotensin II, endothelin, transforming growth factor-
b (TGF-b)] by the remaining nephrons collaborate in
the appearance of structural and functional abnormal-
ities that, if untreated, lead to end-stage renal failure
[6, 7].
In spite of the paramount importance of the renal abla-
tion model in experimental investigation, its clinical coun-
terpart (patients with a severe reduction in the number
of functioning nephrons) has been poorly investigated.
Some studies have reported that patients with a remnant
kidney (RK) (reduction in functioning renal mass of more
than 75% by surgical or medical causes) are at risk to de-
velop proteinuria, hypertension, and glomerulosclerosis
[8–10]. However, in spite of the severe reduction in renal
mass, only a minority of patients in these studies devel-
oped progressive renal insufficiency. The short number
of patients, as well as the short periods of follow-up in
many of them, precluded to clarify which factors could
influence the appearance and progression of renal fail-
ure. Similarly, a considerable risk to develop proteinuria,
glomerulosclerosis, and renal failure has been described
in patients with unilateral renal agenesis (URA) [11–13].
Unlike adult patients suffering a unilateral nephrectomy
in whom the appearance of proteinuria and renal in-
sufficiency is uncommon, patients with URA frequently
show renal abnormalities. It is possible that the frequent
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coexistence of other urologic malformations (vesi-
coureteral reflux, ureteropelvic, and ureterovesical ob-
struction) [14] aggravates nephron loss in patients with
URA, making them more susceptible to the appearance
of hyperfiltration injury. Nevertheless, as in patients with
RK, the reasons why some patients with URA develop
proteinuria and progressive renal insufficiency, whereas
others maintain a normal renal function together with
negative proteinuria during long periods of follow-up, re-
main unknown.
In the present study, we studied a cohort of 54 pa-
tients with a severe reduction in renal mass (33 patients
with URA and 21 with RK) followed in our outpatient
clinic. The long (100 ± 72 months, ranging from 24 to
288 months) and regular follow-up allowed us to identify
several clinical factors influencing the appearance and
progression of renal abnormalities in these patients.
METHODS
We performed a retrospective analysis of all patients
with URA or with an RK (reduction in functioning renal
mass of more than 75%) studied in our outpatient clinic
in the period 1975 to 2002. During this period, 33 patients
were diagnosed as having URA and 21 other patients RK.
After the initial evaluation, all these 54 patients were fol-
lowed at regular intervals at our outpatient clinic. The di-
agnosis of URA was established in 33 patients in whom
radiographic evaluations (excretory urography, renal ul-
trasonography, computed tomography, and renal scans)
discovered a single kidney, without history of surgical re-
moval of the contralateral kidney. The 21 patients with
RK showed a nonfunctioning or absent kidney accompa-
nied by lesions in the contralateral kidney that involved
at least 50% of its parenchyma. Causes of RK were inac-
tive lesions of bilateral renal tuberculosis in 8 patients, bi-
lateral nephrolithiasis with superimposed pyelonephritis
in 5 patients, bilateral chronic pyelonephritis (history of
recurrent urinary tract infections and acute pyelonephri-
tis) in 3 patients, partial nephrectomy by renal cancer in
a solitary kidney in 4 patients (who had had previous
contralateral nephrectomies by renal cancer in 2 cases
and by nephrolithiasis in the other 2 patients), and uni-
lateral nephrectomy in a patient with bilateral angiomy-
olipomas. In all these 21 patients with RK, the complete
absence of renal function in 1 kidney and one half, at
least, of the contralateral kidney was assessed by excre-
tory urography, computed tomography, and radionuclide
renography.
After the initial evaluation, all the patients were in-
structed to perform regular visits in our outpatient clinic.
The duration of follow-up between the initial evalua-
tion until the last visit, death, or onset of chronic dialysis
was calculated in every case. All the patients performed
at least 6 visits, with a mean follow-up of 100 ± 72 months
(range 24 to 288 months).The usual interval between vis-
its was 6 to 12 months, but in patients with severe renal in-
sufficiency the intervals were shortened to 3 to 6 months.
The following data at initial evaluation and at every
visit were obtained from medical records and analyzed
for the present study: age, gender, blood pressure, body
weight, height, serum creatinine (SCr), creatinine clear-
ance (Ccr), and 24-hour proteinuria. In addition, a com-
plete blood count, routine serum biochemistry profile
(including creatinine, glucose, uric acid, calcium, phos-
phorus, sodium, potassium, cholesterol, triglycerides,
total proteins, serum albumin, bilirubin, alkaline phos-
phatase, aspartate aminotransferase, alanine amino-
transferase, and lactate dehydrogenase), urine sediment
examination, and urine culture were obtained in most of
the regular evaluations. Abdominal echographies were
performed usually every 3 to 5 years. All the treatments
received by the patients were carefully obtained from
medical records, with special emphasis in the type, dose,
and duration of antihypertensive drugs. No patient devel-
oped diabetes or other extrarenal disease that could influ-
ence the evolution of renal function during the follow-up.
Blood pressure was measured at every visit with a stan-
dard mercury sphygmomanometer. Systolic and diastolic
blood pressures were measured after 5 minutes of rest
in a sitting position; the average of 2 measurements was
recorded. Mean arterial pressure (MAP) was calculated
as the diastolic blood pressure plus one third of the pulse
pressure. Body mass index (BMI) was calculated as the
weight in kilograms divided by the square of the height
in meters. Obesity was defined as a BMI higher than
30 kg/m2; overweight was defined as a BMI between 25
and 29.9 kg/m2. Renal insufficiency was defined as a SCr
higher than 1.4 mg/dL in men and 1.3 mg/dL in women,
together with a Ccr lower than 60 mL/min/1.73m2.
Renal functional outcome was assessed by the appear-
ance of renal insufficiency, as defined above, or the need
of chronic dialysis. Progression of renal disease was con-
sidered when SCr increased above a 50% of its baseline
value during follow-up. The other major outcome vari-
ables studied were the time to the appearance of protein-
uria persistently (at least in 3 consecutive measurements)
higher than 0.5 g/24 hr, time to requirement of renal re-
placement therapy, and changes in proteinuria.
Statistical analysis
Values are expressed as mean ± SD. For statistical anal-
ysis, the paired and unpaired Student t test and Mann-
Whitney test were used when appropriate. The chi-square
test and Fisher test were used for qualitative variables
when appropriate. The slope of creatinine clearance plot-
ted versus time was calculated in every patient using
linear regression analysis. The study of data evolution
throughout the follow-up was performed by analysis of
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Table 1. Clinical characteristics at presentation
Total (N = 54) URA (N = 33) RK (N = 21) P value
Age years 46.5 ± 15 (18–72) 41 ± 16 (18–67) 52 ± 11 (33–72) 0.004
Gender M; F 32; 22 23; 10 9; 12 0.094
MAP mm Hg 98 ± 16 (70–136) 99 ± 17 (70–136) 95 ± 14 (73–123) NS
SCr mg/dL 1.8 ± 1 (0.7–6.3) 1.9 ± 1.2 (0.7–6.3) 1.6 ± 0.6 (0.9–4.1) NS
CCr mL/min/1.73m2 59.5 ± 28 (14–137) 59 ± 31 (14–137) 61 ± 25 (22–113) NS
Proteinuria g/24h 1.3 ± 1.7 (0–7) 1.8 ± 2 (0–7) 0.6 ± 0.7 (0–3.5) 0.011
Serum cholesterol mg/dL 210 ± 83 (146–299) 206 ± 76 (146–285) 212 ± 75 (155–299) NS
BMI kg/m2 27.1 ± 6.7 (17.7–45) 27.3 ± 8.3 (17.7–45) 27 ± 5.7 (19–39) NS
Patients with BMI <25 20 12 8
Patients with BMI 25–29.9 16 10 6 NS
Patients with BMI ≥30 18 11 7
Follow-up months 100 ± 72 (24–288) 80 ± 71 (24–252) 120 ± 89 (24–288) NS
variance for repeated measurements (ANOVA). The cu-
mulative probability of absence of proteinuria, normal
renal function, and progression of renal insufficiency was
estimated by survival analysis according to the Kaplan-
Meier method, and log-rank test was used for comparison
of different groups. Stepwise multiple logistic regression
analysis was performed to determine the inference of dif-
ferent parameters at baseline or during follow-up on the
development of proteinuria and progression of renal in-
sufficiency. Logistic regression was performed by exact
methods. P values lower than 0.05 were considered as
statistically significant. Statistical analysis was performed
using SPSS 10.0.7 for Windows software (Chicago, IL,
USA).
RESULTS
Patient characteristics at presentation
Clinical characteristics at presentation of the 54 pa-
tients with severe reduction in renal mass included in the
study are expressed in Table 1. Thirty-three patients have
URA and 21 RK due to different causes (renal tuber-
culosis, nephrolithiasis, chronic pyelonephritis, bilateral
tumors) as described in Methods. Patients with RK were
significantly older than those with URA and had a signifi-
cantly lower proteinuria at presentation (Table 1). There
was a higher proportion of males among patients with
URA but this difference did not reach statistical signifi-
cance. BMI was very similar between patients with URA
(27.3 ± 8.3 kg/m2) and RK (27 ± 5.7 kg/m2). As it is shown
in Table 1, 20 patients had a BMI lower than 25 kg/m2,
16 showed overweight (BMI 25–29.9 kg/m2), and 18 were
obese (BMI ≥ kg/m2), without significant differences be-
tween patients with URA or RK. Those patients with a
BMI lower than 25 kg/m2 at presentation showed a lower
MAP than those with a BMI ≥25 kg/m2 (94.8 ± 15 vs.
99.5 ± 16 mm Hg), but this difference did not reach sta-
tistical significance.
As it is shown in Table 2, 20 out of the 54 patients
showed a normal renal function and negative protein-
uria at presentation (group 1). The remaining 34 pa-
tients (group 2) showed proteinuria (2.1 ± 1.6 g/day;
range 0.8–7) and/or renal insufficiency (SCr 2.3 ± 1.1
mg/dL; range 1.3–6.3 and Ccr 42 ± 14 mL/min/1.73m2;
range 14–69). There were no differences between both
groups in the proportion of males/females or in the
proportion of patients with URA or RK. Group 2 pa-
tients were significantly older than group 1 (50 ± 13
vs. 40 ± 15 years, P = 0.0109), and their blood pres-
sure was significantly higher (MAP 102 ± 17 vs. 90 ±
12 mm Hg, P = 0.007). BMI was significantly higher
in group 2 patients (29 ± 7.4 vs. 24 ± 4.1 kg/m2,
P = 0.0026). There were 11 (55%) patients in group 1
with a BMI lower than 25 kg/m2, 4 (20%) with BMI be-
tween 25 and 29.9 kg/m2, and 5 (25%) with a BMI higher
than 30 kg/m2. The number of group 2 patients with these
BMI values were 9 (26%), 12 (35%), and 13 (38%), re-
spectively (comparison of patients with BMI <25 kg/m2
and >25 kg/m2 between groups 1 and 2, P = 0.045)
(Table 2). Mean follow-up was 109 ± 84 months in group
1 and 94 ± 65 months in group 2.
Evolution of patients with normal renal function and
absence of proteinuria at presentation (group 1)
Eleven (55%) patients of group 1 maintained a nor-
mal renal function and negative proteinuria throughout
a follow-up of 114 ± 78 months (r 24–240) (group 1A). Six
out of these 11 patients had URA and the remaining 5 pa-
tients RK. The remaining 9 (45%) patients (6 with URA
and 3 with RK) developed proteinuria during a follow-up
of 103 ± 95 months (r 24–288) (group 1B). In group 1B pa-
tients, the appearance of proteinuria was slowly progres-
sive; it reached nephrotic range (higher than 3.5 g/day) in
3 patients, although none of them showed hypoalbumine-
mia or edema. Mean interval between initial evaluation
and the appearance of proteinuria higher than 0.5 g/day
was 40 ± 22 months (r 5–69). At the end of follow-up,
proteinuria was 2.4 ± 1.3 g/day (r 1–4.5). Three patients
of group 1B developed renal insufficiency, preceded in
every case by the appearance of proteinuria. Progression
of renal insufficiency in these 3 patients was slow, none of
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Table 2. Clinical features of group 1 patients (normal renal function and negative proteinuria at presentation) and group 2 patients (proteinuria
or renal insufficiency at presentation)
Group 1 (N = 20) Group 2 (N = 34) P value
Age years 40 ± 15 (18–72) 50 ± 13 (19–72) 0.0109
Gender M/F 10/10 22/12 NS
URA/RK 12 (60%)/8 (40%) 21 (62%)/13 (38%) NS
MAP mm Hg 90(± 12 (70–120) 102 ± 17 (73–136) 0.007
SCr mg/dL 1.1 ± 0.2 (0.7–1.4) 2.3 ± 1.1 (1.1–6.3) 0.0001
CCr mL/min/1.73m2 89 ± 20 (65–137) 42 ± 14 (14–69) 0.0001
Proteinuria g/24h 0 2.1 ± 1.6 (0.8–7) 0.0001
Serum cholesterol mg/dL 198 ± 73 (146–270) 221 ± 82 (176–299) NS
BMI kg/m2 24 ± 4.1 (19–30.5) 29 ± 7.4 (17.7–45) 0.0026
Patients with BMI <25 11 9
Patients with BMI 25–29.9 4 12 0.045a
Patients with BMI ≥30 5 13
Follow-up months 109.5 ± 84 (24–288) 94.5 ± 65 (24–228) NS
Smokers 2 (10%) 8 (23,5%) NS
aComparison of patients with BMI <25 kg/m2and >25 kg/m2.
Table 3. Clinical findings at presentation in group 1 patients with a favorable evolution (group 1A) and those that developed proteinuria/renal
insufficiency (group 1B)
Group 1A (N = 11) Group 1B (N = 9) P value
Age years 35 ± 18 (18–72) 46 ± 7 (36–57) NS
Gender M/F 5/6 5/4 NS
URA/RK 6/5 6/3 NS
MAP mm Hg 87 ± 115 (70–120) 94 ± 7 (83–103) NS
SCr mg/dL 1 ± 0.2 (0.7–1.4) 1.1 ± 0.2 (0.8–1.4) NS
CCr mL/min/1.73m2 93 ± 22 (61–137) 84 ± 18 (70–113) NS
Proteinuria g/24h 0 0
Serum cholesterol mg/dL 191 ± 69 (146–244) 205 ± 73 (175–270) NS
BMI kg/m2 21.6 ± 2.6(19–28) 27 ± 3.6 (23–30.5) 0.02
Patients with BMI <25 10 1
Patients with BMI 25–29.9 1 3 0.0009a
Patients with BMI ≥ 30 0 5
Smokers 1 (9%) 1 (11%) NS
aComparison of patients with BMI <25 kg/m2and >25 kg/m2.
them reaching end-stage renal failure (final SCr 1.6, 1.7,
and 2 mg/dL, respectively). The 6 remaining patients of
group 1B maintained a normal renal function throughout
follow-up in spite of persistent proteinuria.
Comparison between groups 1A and 1B at presenta-
tion (Table 3) showed that those patients that later de-
veloped proteinuria and renal insufficiency (group 1B)
had a BMI significantly higher than those with a fa-
vorable evolution. Whereas only 1 patient of group 1A
showed overweight at presentation, 3 patients of group
1B showed overweight, and 5 were obese (comparison
of patients with BMI <25 kg/m2 and >25 kg/m2 between
groups 1A and 1B, P = 0.0009) (Table 3). Mean age and
blood pressure were higher in group 1B but the differ-
ences did not reach statistical significance. Renal func-
tion (SCr and Ccr), as well as serum cholesterol levels
and the proportion of smokers, was similar between both
groups.
During the follow-up, there were no significant differ-
ences in blood pressure between group 1A and 1B. Four
patients of group 1A (36%) were treated with ACE in-
hibitors (ACEI) from the onset of follow-up, whereas
3 patients of group 1B (33%) were treated with ACEI,
and 1 other (11%) with angiotensin receptor antagonists
(ARB). One patient in group 1A (9%) and 2 in group 1B
(22%) received dihydropiridine calcium channel block-
ers from the onset of follow-up. These differences in the
type of antihypertensive agents received by group 1A and
1B patients did not reach statistical significance.
Although BMI tended to increase in group 1A, the
significant differences in BMI that both groups showed
at presentation persisted throughout the follow-up. As
it is shown in Figures 1 and 2, the probabilities of ab-
sence of proteinuria and normal renal function were sig-
nificantly influenced by BMI: after 5 years of follow-up,
they were 25% and 75%, respectively, in patients with
obesity or overweight (BMI>25 kg/m2), and 100% and
100%, respectively, in patients with BMI <25 kg/m2. Af-
ter 15 years of follow-up these probabilities were 13%
and 62% in patients with BMI> 25 kg/m2, and 92% and
100% in patients with BMI lower than 25 kg/m2 (Figs. 1
and 2).
By univariate analysis, BMI at presentation, analyzed
as a continuous variable, was the only factor statistically
associated with the risk to develop proteinuria/renal in-
sufficiency in group 1 patients (Table 4).
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Fig. 1. Probability of absence of proteinuria in group 1 patients with
BMI >25 kg/m2 (dashed line) and <25 kg/m2 (solid line) (log-rank test,
P = 0.0006).
100
80
60
40
20
0
Pa
tie
nt
s 
w
ith
 n
or
m
a
l r
en
al
fu
nc
tio
n,
 %
0 2 4 6 8 10 12 14 16
Follow-up, years
Fig. 2. Probability of normal renal function in group 1 patients with
BMI >25 kg/m2 (dashed line) and <25 kg/m2 (solid line) (log-rank
test, P < 0.02).
Evolution of patients with proteinuria/renal insufficiency
at presentation (group 2)
The clinical characteristics of patients showing protein-
uria/renal insufficiency at presentation (group 2) are ex-
pressed in Table 2. Twenty-one patients (62%) had URA
and 13 (38%) RK. Mean follow-up was 94 ± 65 months
(r 24–228). For the whole group, renal function showed a
progressive deterioration; mean SCr at the end of follow-
up was significantly higher than at presentation (4.2 ± 3.1
vs. 2.3 ± 1.1 mg/dL, P = 0.001), and Ccr significantly lower
(32 ± 22 vs. 42 ± 14 mL/min/1.73m2, P = 0.003). Protein-
uria tended to increase (2.4 ± 2.6 vs. 2.1 ± 1.6 g/24 h
at presentation). Twelve (35%) patients started chronic
dialysis during follow-up, and 1 died.
Renal function remained stable in 20 patients of this
group (group 2A). In the remaining 14 patients (group
2B), progression of renal insufficiency (increase of SCr
higher than 50% of its baseline value) was observed.
When comparing groups 2A and 2B at presentation
(Table 5), several significant differences were observed:
SCr and BMI were significantly higher among group 2B
Table 4. Variables influencing the appearance of proteinuria/renal
insufficiency in group 1 patients
Univariate analysis
Variable P value Odds ratio 95% CI
Age years 0.14
Gender 0.65
MAP mm Hg 0.24
BMI kg/m2 0.03 1.64 1.07–2.51
SCr mg/dL 0.26
CCr mL/min/1.73m2 0.33
Serum cholesterol mg/dL 0.30
Follow-up months 0.76
Smoking 0.88
patients. Whereas 9 patients of group 2A (45%) had a
BMI lower than 25 kg/m2, all patients of group 2B were
overweight or obese (comparison of patients with BMI
<25 kg/m2 and >25 kg/m2 between groups 2A and 2B,
P = 0.004) (Table 5). There were no significant differ-
ences in the remaining clinical variables analyzed (age,
gender, etiology of renal mass reduction, blood pres-
sure, serum cholesterol levels, proteinuria, or duration
of follow-up). Most of group 2B patients (12/14 patients)
initiated chronic dialysis during the follow-up.
A very significant difference in the proportion of pa-
tients treated with ACEI/ARB was observed between
both groups: 18 patients (90%) (17 with ACEI and 1
with ARB) in group 2A versus 4 patients (28%) (3
with ACEI and 1 with ARB) in group 2B (P = 0.0005)
(Table 5). Those patients (N = 22) of group 2 that were
treated with ACEI/ARB since initial evaluation, showed
a more favorable course than that of the remaining 12
patients that did not receive such medications. Ccr de-
creased from 49 ± 17 to 22 ± 21 mL/min (P = 0.0001) in
patients without ACEI/ARB, and from 39 ± 15 to 37 ±
20 mL/min in patients treated with these drugs. Loss of
glomerular filtration rate, estimated by Ccr, was −0.22
mL/min/year in patients treated with ACEI/ARB and
−3 mL/min/year in patients without these medications
(P = 0.001). The probability of progression of renal in-
sufficiency was significantly lower among those patients
treated with ACEI/ARB (Fig. 3). Proteinuria showed a
decrease from 2.2 ± 2 to 1.5 ± 1.3 g/24 hr (P = 0.0001)
after 3 years of follow-up in those patients of group 2 that
were treated with ACEI/ARB, whereas it tended to in-
crease (from 1.8 ± 1.1 to 2.7 ± 2.6; P = 0.042) in those
that did not receive this treatment. Two patients in group
2A (10%) and 3 in group 2B (21%) were treated with
dihydropiridine calcium channel blockers.
By univariate analysis, BMI at presentation, as well as
treatment with ACEI/ARB, were the only factors statisti-
cally associated with the risk for renal failure progression
among the 34 patients of group 2. By multivariate analy-
sis, both BMI at presentation (P = 0.022; OR 1.57, 95%
CI 1.08–2.27) and treatment with ACEI/ARB (P = 0.018;
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Table 5. Clinical characteristics of group 2 patients (proteinuria/renal insufficiency) with a stable clinical course (group 2A) or with progressive
renal insufficiency (group 2B)
Group 2A (N = 20) Group 2B (N = 14) P value
Age years 50 ± 14 (19–72) 50 ± 10 (22–64) NS
Gender M/F 13 (65%)/7 (35%) 9 (64,3%)/5 (35,7%) NS
MAP mm Hg 101 ± 17 (76–128) 104 ± 17(73–136) NS
URA/RK 12 (60%)/8 (40%) 9 (64.3%)/5 (35.7%) NS
SCr mg/dL 1.9 ± 0.6 (1.3–4.1) 2.7 ± 1.5 (1.5–6.3) 0.045
CCr mL/min/1.73m2 45 ± 16 (22–85) 39 ± 17 (14–68) NS
Proteinuria g/24h 1.6 ± 1.6 (0.5–6) 2.6 ± 1.9 (0.5–7) NS
Serum cholesterol mg/dL 214 ± 77 (176–253) 226 ± 86 (180–299) NS
BMI kg/m2 24.6 ± 4.6 (17.8–37) 35.3 ± 5.9 (29.8–45) 0.0003
Patients with BMI <25 9 0
Patients with BMI 25–29.9 7 5 0.004a
Patients with BMI ≥30 4 9
Follow-up months 99 ± 66 (24–228) 87 ± 66 (24–216) NS
Treatment with ACEI/ARB 18 (90%) 4 (28%) 0.0005
Smoking 3 (15%) 5 (35%) NS
Dialysis 0 12 (85.7%) 0.0001
Death 0 1 (7.1%) NS
aComparison of patients with BMI <25 kg/m2and >25 kg/m2.
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Fig. 3. Probability of progression of renal insufficiency among group
2 patients treated with ACEI/ARB (solid line) or not (dashed line)
(log-rank test, p 0.02).
OR 0.08, 95% CI 0.019–0.36) remained as statistically sig-
nificant risk factors (Table 6).
Final outcome of the whole cohort of patients
At the end of follow-up, only 11 patients (20%; group
1A, Table 3) maintained a normal renal function without
proteinuria. In the remaining 43 patients (80%), protein-
uria was observed at presentation (34 patients, group 2)
or developed during follow-up (9 patients, group 1B).
One patient died, and 12 (24%) started chronic dialysis
during follow-up. Twenty-three patients showed chronic
renal insufficiency, and the remaining 7 patients showed
proteinuria (ranging from 0.9 to 4 g/24 hr) with normal
renal function at the end of follow-up.
DISCUSSION
In contrast to the impressive number of experimental
studies investigating the mechanisms of progression and
the therapeutic approaches in the renal ablation model,
clinical data about the clinical counterpart of this condi-
tion, that is, patients with a severe reduction of renal mass,
are rather scarce. Three clinical studies published in 1991
[8–10] gathered 33 patients with an RK (partial nephrec-
tomy in patients with only 1 functioning kidney, resulting
in the loss of more than 60% of the total renal mass). Al-
though a considerable proportion of patients developed
proteinuria and some of them end-stage renal failure, the
authors emphasized that renal function remained stable
in the majority of cases, and that some patients did not
show any sign of renal disease (proteinuria or GFR de-
crease) in spite of the severe nephron loss. These clinical
studies raised skepticism about the simplistic translation
of the findings of the RK model in rats to the human being,
remarking that some humans with a remnant kidney can
live a long life with stable renal function [15]. Similarly,
some studies showed that patients with URA, the most
common cause of congenital reduction in nephron num-
ber, are at increased risk of the appearance of proteinuria,
hypertension, and renal insufficiency [11–13]. However,
no previous study has clarified the reason why only some
patients with URA develop these complications.
The most salient finding of our study that sheds light
on this unpredictable evolution of patients with RK and
URA is the fundamental impact of BMI on the out-
come of these patients. We found that patients presenting
proteinuria or renal insufficiency at the first evaluation
(group 2) had a BMI significantly higher than those with
normal renal function and negative proteinuria (group
1) (Table 2). Moreover, among the latter, those patients
that developed proteinuria or renal insufficiency during
follow-up (group 1B) showed a significantly higher BMI
than that of patients that remained normal (group 1A)
(Table 3). Probability of negative proteinuria and normal
renal function during follow-up in group 1 patients were
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Table 6. Variables influencing the progression of renal insufficiency in group 2 patients
Univariate analysis Multivariate analysis
Variable P value Odds ratio 95% CI P value Odds ratio 95% CI
Age years 0.88
Gender 0.96
MAP mm Hg 0.6
BMI kg/m2 0.009 1.47 1.12–1.97 0.022 1.57 1.08–2.27
SCr mg/dL 0.11
CCr mL/min/1.73m2 0.33
Proteinuria g/24h 0.19
ACEI treatment 0.0025 0.04 0.006–0.28 0.018 0.08 0.019–0.36
Follow-up months 0.59
Smoking 0.18
significantly higher among patients without overweight
(BMI <25 kg/m2) (Figs. 1 and 2). BMI was the only signif-
icant risk factor for the appearance of proteinuria/renal
insufficiency in these patients (Table 4).
Overweight also played a crucial role in the outcome
of patients already showing renal abnormalities at pre-
sentation (group 2). Those patients in whom renal insuf-
ficiency progressed (50% increase of baseline SCr, group
2B) had BMI significantly higher than those with stable
renal function during follow-up (group 2A) (Table 5), and
BMI was a significant risk factor for the progression of
renal failure both in univariate and multivariate analysis
(Table 6).
Why does overweight predispose patients with URA
and RK to the appearance and progression of renal
injury in such a determinant manner? Recent findings
about the influence of obesity on renal function can an-
swer this question. Experimental and clinical studies have
demonstrated that obesity induces important renal hemo-
dynamic changes consistent with glomerular hyperper-
fusion and hyperfiltration. An increase of GFR, RPF,
glomerular pressure, and filtration fraction through a di-
lated glomerular afferent arteriole, has been repeatedly
found in experimental models of obesity [16, 17] and
in obese subjects [17, 18]. These changes are very rem-
iniscent of the hemodynamic maladaptive changes that
follow extensive renal ablation in experimental studies
[2–4]. In addition, it has been recently demonstrated that
obesity-related hyperfiltration improves substantially af-
ter weight loss [19]. The mechanisms through which over-
weight induces the commented hemodynamic changes
have been partially clarified in the last years. An in-
creased renal sodium reabsorption has been observed in
obesity, and this impaired natriuresis likely plays an im-
portant role in the vasodilation of afferent glomerular
arteriole and the consequent transmission of increased
arterial pressure to the glomerular capillary [17, 18, 20].
Several experimental findings point out increased re-
nal sympathetic activity and activation of the renin-
angiotensin system as the most important stimulus for
obesity-related increased renal sodium reabsorption [17].
Experimental studies in animal models of obesity, such as
the Zucker rat, have shown that the glomerular hyperten-
sion induced by obesity causes, in the long term, glomeru-
lar injury and progressive glomerulosclerosis [21].
Hyperinsulinemia, hypertrigliceridemia, activation of the
renin-angiotensin system, and the increased synthesis of
several fibrogenic substances (TGF-b , leptin) collaborate
in the renal damage [22–24].
Glomerulosclerosis and progressive renal insufficiency
have been reported in obese patients with a normal renal
mass [25–26]. Therefore, it is very conceivable that renal
damage due to obesity-related hyperfiltration should be
especially severe in patients with a concomitant reduction
in renal mass by congenital (as in patients with URA) or
acquired (as in RK) causes. The relationship between a
reduced nephron number and a particular susceptibility
to obesity-related renal damage that we have found in
this study also agrees with a previous study of our group
in which we showed that the majority of patients that de-
veloped proteinuria after a unilateral nephrectomy were
obese [27]. On the other hand, recent studies have shown
a detrimental effect of overweight on the progression of
other renal diseases, such as IgA nephropathy [28].
Another important finding in our study was the clear
beneficial influence of ACEI or ARB treatment on the
outcome of patients showing renal damage at presenta-
tion (group 2). Ninety percent of those patients with a
favorable evolution (no derangement of renal function
throughout follow-up) had been treated with ACEI/ARB
since the start of follow-up, whereas only 4 out of 14 pa-
tients (28%) showing a progressive renal insufficiency
had received these treatment (Table 5). Loss of GFR
was significantly slower in group 2 patients treated with
ACEI/ARB (−0.22 mL/min/year) than in those patients
that were not (−3 mL/min/year), and the probability
of renal function stabilization was significantly higher
among those patients treated with ACEI/ARB (Fig. 3).
The experimental renal ablation model was the sce-
nario in which the potent renoprotective influence of
ACEI was first demonstrated [4, 5]. Our study confirms
in a clinical setting the beneficial effect of ACEI/ARB
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on this type of renal damage associated with renal mass
reduction. Of note, very few clinical studies have specifi-
cally addressed the long-term influence of this treatment
on the outcome of hyperfiltration-related renal diseases.
Our study has several limitations inherent to its retro-
spective character; included patients were collected over
a wide period of time and treatment with ACEI/ARB was
not randomized. However, it should be considered that,
given the very slow progression of hyperfiltration-related
renal diseases, prospective studies enrolling a sufficient
number of patients are very difficult to perform. On the
other hand, we think that our findings have important
implications for clinical practice.
CONCLUSION
Those patients with a severe reduction of renal mass
should be warned about the harmful consequences of
overweight on the appearance and progression of re-
nal complications, and obesity should be carefully pre-
vented and treated. Periodic controls should be per-
formed watching for the appearance of hypertension or
proteinuria. In this case, ACEI or ARB should be pre-
scribed. The epidemic increase of overweight and obesity
all over the world reinforces the importance of our ob-
servations.
Reprint requests to Dr. Manuel Praga, Servicio de Nefrologı´a, Hos-
pital 12 de Octubre, Ctra de Andalucia, Km 5,400 28041 Madrid, Spain.
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